Quantcast
Last updated on April 16, 2014 at 11:25 EDT

Latest American Society of Hematology Stories

2012-12-10 15:17:53

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. The studies evaluate long-held treatment standards and whether modifications in intensity and duration of therapy may offer equally effective outcomes while reducing toxicities and relapse rates. Although significant advances have been made in delivering new and improved therapies for...

2012-12-10 15:13:30

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs,...

2012-12-10 12:24:46

Data highlights opportunities to prevent hospital readmissions, reduce health-care costs, and improve long-term care ATLANTA, Dec. 10, 2012 /PRNewswire-USNewswire/ -- Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH). Sickle cell disease (SCD) is an inherited, chronic blood disorder affecting between 90,000 and...

2012-12-10 08:26:12

63% of American respondents presenting at the American Society of Hematology annual meeting used NIH funding to support their study ATLANTA, Dec. 10, 2012 /PRNewswire-USNewswire/ -- A survey highlighting the correlation between today's cutting edge medical research and the National Institutes of Health (NIH) funding was released today at the 54th Annual Meeting of the American Society of Hematology (ASH), the preeminent medical meeting for physicians and scientists in hematology that...

2012-12-09 16:20:28

- 68% transfusion independence response rate and 37% durable spleen response rate - MISSISSAUGA, ON, Dec. 9, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported updated results from the 166 patient Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were presented this afternoon in an oral session at the 54(th) Annual Meeting of the American Society of Hematology underway in Atlanta, Georgia. --...

2012-12-09 12:20:12

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell...

2012-12-09 08:20:16

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have...

2012-12-08 16:20:18

ATLANTA, Dec. 8, 2012 /PRNewswire-USNewswire/ -- Studies presented today at the 54th( )Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. The studies evaluate long-held treatment standards and whether modifications in intensity and duration of therapy may offer equally effective outcomes while reducing toxicities and relapse rates. Although significant advances have been made...

2012-12-08 12:20:19

ATLANTA, Dec. 8, 2012 /PRNewswire-USNewswire/ -- Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how...

2012-12-06 16:24:09

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the launch of the Make Your Mark at the Multiple Myeloma Experience at the 54(th) American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia on December 8, 2012. The experience is designed to celebrate progress made in the treatment of multiple myeloma, an incurable blood cancer, and encourage members of the multiple myeloma community to make their...